| 62.62 1.28 (2.09%) | 08-21 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 74.5 | 1-year : | 87.02 |
| Resists | First : | 63.79 | Second : | 74.5 |
| Pivot price | 58.83 |
|||
| Supports | First : | 56.79 | Second : | 52.47 |
| MAs | MA(5) : | 61.45 |
MA(20) : | 57.77 |
| MA(100) : | 55.52 |
MA(250) : | 50.02 |
|
| MACD | MACD : | 1.6 |
Signal : | 1.2 |
| %K %D | K(14,3) : | 87.6 |
D(3) : | 89.2 |
| RSI | RSI(14): 62.6 |
|||
| 52-week | High : | 65 | Low : | 29.87 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ PCVX ] has closed below upper band by 13.2%. Bollinger Bands are 17.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 63.08 - 63.38 | 63.38 - 63.65 |
| Low: | 61.12 - 61.47 | 61.47 - 61.78 |
| Close: | 62.09 - 62.64 | 62.64 - 63.11 |
Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and counter antimicrobial resistance; VAX-A1, a conjugate vaccine formulation aimed at Group A Streptococcus; and VAX-PG, a novel protein vaccine specifically developed to target the key pathogen responsible for periodontitis. The organization, which was initially established as SutroVax, Inc., officially rebranded as Vaxcyte, Inc. in May 2020. Founded in 2013, its corporate headquarters are situated in San Carlos, California.
Tue, 18 Aug 2026
Vaxcyte: Not Enough Safety Margin With Current Price (NASDAQ:PCVX) - Seeking Alpha
Mon, 17 Aug 2026
Vaxcyte, Inc. (PCVX) Stock Analysis: Unraveling The 87.70% Potential Upside - DirectorsTalk Interviews
Sat, 15 Aug 2026
Will Vaxcyte's (PCVX) Expanded Losses and Fully Enrolled VAX-31 Trials Reframe Its Risk‑Reward Narrative - simplywall.st
Mon, 10 Aug 2026
Bank of America Corp DE Increases Position in Vaxcyte, Inc. $PCVX - MarketBeat
Wed, 05 Aug 2026
Vaxcyte (Nasdaq: PCVX) posts $605M YTD loss and $2.5B cash balance - Stock Titan
Mon, 03 Aug 2026
PCVX (PCVX) holder plans August 3 sale after option exercise - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 149 (M) |
| Shares Float | 136 (M) |
| Held by Insiders | 0.4 (%) |
| Held by Institutions | 110.6 (%) |
| Shares Short | 14,230 (K) |
| Shares Short P.Month | 14,630 (K) |
| EPS | -7.64 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 20.76 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -22.7 % |
| Return on Equity (ttm) | -36.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -7.73 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -881 (M) |
| Levered Free Cash Flow | -497 (M) |
| PE Ratio | -8.21 |
| PEG Ratio | 0 |
| Price to Book value | 3.01 |
| Price to Sales | 0 |
| Price to Cash Flow | -10.58 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|